References
- Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45–53.
- Regan MM, Price KN, Giobbie-Hurder A, Thurlimann B, Gelber RD. Interpreting breast international group (BIG) 1–98: A randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res 2011;13:209.
- Viale G, Regan MM, Dell’Orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, et al. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1–98 randomized trial. Ann Oncol 2011;22:2201–7.
- Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine theraphy in postmenopausal breast cancer patients: A systematic review and meta-analysis. J Nat Cancer Inst 2011;103:1299–309.
- Toft Sorensen H, Lash T, Rothman K. Beyond randomized controlled trials: A critical comparison of trials with nonrandomized studies. Hepatology 2006;44:1075–82.
- Patnaik JL, Byers T, Diguiseppi C, Denberg TD, Dabelea D. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst 2011;103:1101–11.
- Ismail AA, Pye SR, Cockerill WC, Lunt M, Silman AJ, Reeve J, et al. Incidence of limb fracture across Europe: Results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 2002;13:565–71.
- Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK. International variations in hip fracture probabilities: Implications for risk assessment. J Bone Miner Res 2002;17:1237–44.